CBG-131

N/A

Report date: 2026/02/10 20:00:22

Base Information

Drug NameCBG-131
Drug Alias NameCBG131CBG-131
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsClaudin 18 protein modulators
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCarbiogene Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCarbiogene Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A